Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

Clinical trial NCT04557956 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04557956
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Melanoma

Start date: 2021-08-19
Primary completion: 2025-10-15
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.